Efficacy of lorlatinib after failure of a first-line ROS1 tyrosine kinase inhibitor (ROS1 TKI) in patients (pts) with advanced ROS1-positive non-small cell lung cancer (ROS1+ NSCLC)
Auteurs / Authors: M. Duruisseaux, C. Ardin, C. Mascaux, F. Bigot, S. Cousin, F. Guisier, A. Rabeau, M.C. Willemin, M. Zysman, A.B. Cortot, I. Monnet, A. Swalduz, P-J. Souquet, A. Langlais, F. Morin, F. Escande, V. Westeel, D. Moro-Sibilot
Journal / Conference: ESMO
Année / Year: 2025
PMID: Oral abstract
Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(25)03531-8/fulltext
